| # | Title | Journal | Year | Citations |
|---|
| 1 | Community-acquired pneumonia | Lancet, The | 2015 | 392 |
| 2 | New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study | American Journal of Respiratory and Critical Care Medicine | 2017 | 142 |
| 3 | A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia | Chest | 2017 | 136 |
| 4 | The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship | Intensive Care Medicine | 2017 | 103 |
| 5 | Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review | Respiratory Medicine | 2018 | 90 |
| 6 | Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFβ1 | BMC Pulmonary Medicine | 2014 | 77 |
| 7 | Early Bacterial Identification among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Clinical Trial | American Journal of Respiratory and Critical Care Medicine | 2021 | 65 |
| 8 | Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study | Critical Care | 2022 | 46 |
| 9 | Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations | Clinical Pharmacokinetics | 2016 | 42 |
| 10 | A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1 | Clinical Infectious Diseases | 2018 | 41 |
| 11 | A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study) | Antimicrobial Agents and Chemotherapy | 2018 | 30 |
| 12 | A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens | Clinical Therapeutics | 2017 | 18 |
| 13 | Tracheostomy Timing and Outcome in Severe COVID-19: The WeanTrach Multicenter Study | Journal of Clinical Medicine | 2021 | 18 |
| 14 | Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe | Diagnostic Microbiology and Infectious Disease | 2018 | 16 |
| 15 | Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections | International Journal of Antimicrobial Agents | 2018 | 15 |
| 16 | Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program | Infectious Diseases and Therapy | 2021 | 15 |
| 17 | Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials | Current Opinion in Infectious Diseases | 2021 | 13 |
| 18 | Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe | Diagnostic Microbiology and Infectious Disease | 2019 | 11 |
| 19 | Respiratory infections | European Respiratory Review | 2022 | 7 |
| 20 | Lateral position during severe mono-lateral pneumonia: an experimental study | Scientific Reports | 2020 | 6 |
| 21 | Community-acquired pneumonia: Changing paradigms about mortality | Community Acquired Infection | 2014 | 5 |
| 22 | New developments in the diagnosis of VAP make bronchoalveolar lavage less useful: some considerations | Intensive Care Medicine | 2014 | 4 |
| 23 | A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections | Journal of Medical Microbiology | 2020 | 3 |
| 24 | Pneumonia in 2016: towards better care | Lancet Respiratory Medicine,the | 2016 | 2 |
| 25 | The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens | Diagnostic Microbiology and Infectious Disease | 2018 | 2 |
| 26 | Importance of a registered and structured protocol when conducting systematic reviews: comments about nebulized antibiotics for ventilator-associated pneumonia | Critical Care | 2015 | 1 |
| 27 | Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant Staphylococcus aureus Pneumonia | Antimicrobial Agents and Chemotherapy | 2020 | 1 |
| 28 | The efficacy of telavancin in comparison to linezolid on endotracheal tube biofilm in pigs with MRSA pneumonia | | 2022 | 0 |
| 29 | Community-acquired pneumonia: Changing paradigms about mortality | Community Acquired Infection | 0 | 0 |
